The Wockhardt Group, previously a prominent player in the pharmaceutical industry, is facing financial distress. With mounting debts and a struggling business, the group's substantial assets are now headed to market. This dramatic turn of events has sent shockwaves through the industry, raising eyebrows among analysts. It remains unknown who will